Fundamental analysis by بازارهای مالی با وحید درزی about Stock کاسپین on 11/19/2020

Coding #Caspian Company: Caspian Pharmacy Course: 6 -month -old audited Stock number: 700m Floating stock: 15% Major Shareholder: Procedure Pharmaceutical Investment Company (General Corporation) with 21.76% Share Internal Sales: 93% Foreign Sales: 7% Sales Performance: 7% increase over the same period last year Production Performance: 19% increase over the same period of the previous year Operational revenue changes: 36% increase Operational Profit Changes: 29% Increase Net Profit Changes: 19% Increase Profit Changes per share (EPS): %19 Description: The company has identified 580 Rials and 6 months 1,446 Rials. The company has identified 202,949 million riyals from sales and 295,443 million Rials. The cost of the finished 40% increased. Due to the increase in operational revenue, gross profit has increased by 33%. Sales, public and general costs increased by 33% and other operating costs of 6,624%. Other operational revenues have increased by 80%. Financial costs have increased by 156%. Other non -operational income from the investment site has been identified 131 million rials; However, this account was worth 332 million rials in the same period last year. Other non -operational revenues have increased by 386% from miscellaneous items. Sales of domestic and foreign products are the highest to the least, respectively, injectable and non -injectable. The raw materials and packaging materials of the company are prepared domestically and imported. Assessment Result: Positive Tips 10, Negative Tips 4, Low Tips 1 @vahid_darzi